Trials / Not Yet Recruiting
Not Yet RecruitingNCT07447024
Selected Exercise Program on Upper Cross Syndrome Post-unilateral Mastectomy
- Status
- Not Yet Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- Sponsor
- Cairo University · Academic / Other
- Sex
- Female
- Age
- 45 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to evaluate the therapeutic efficacy of exercise rehabilitation program on upper limb range and forward head posture post unilateral radical mastectomy.
Detailed description
Upper cross syndrome (forward head posture and rounded shoulder) is a major problem facing physical therapist, which causes an increase in pain, limitation of quality of life and delayed rehabilitation process. The lack in knowledge and information in the published studies about effects of exercise program in forward head posture and rounded shoulder in female's management post unilateral mastectomy. This study will be carried out to investigate the effectiveness exercise program in improving the range of motion in shoulder and forward head posture in females post unilateral mastectomy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Selected exercise program | Patients who have upper cross syndrome post unilateral modified radical mastectomy and who will receive exercise program (strengthening, active range of motion exercise, and strengthening exercises including prone scapular stabilization, shoulders shrug McKenzie exercise for neck, repeated shoulder horizontal adduction, repeated shoulder flexion, repeated shoulder extension, neck flexion McKenzie exercises) and routine medical treatment. Patients will receive 3 sessions per week for 12weeks, time of session is 45 minutes. |
| DRUG | Routine medical therapy | For pain relief: Acetaminophen: 2 pills two times per day. Ibuprofen 400 mg: 1 pill two times per day. Hormonal therapy: Tamoxifen 20 mg: once daily. Silicone gel creams (Biocorneum): 3 times per day. These medications will be given for all patients throughout the treatment period (12 weeks). |
Timeline
- Start date
- 2026-03-02
- Primary completion
- 2026-06-07
- Completion
- 2026-06-15
- First posted
- 2026-03-03
- Last updated
- 2026-03-03
Locations
1 site across 1 country: Egypt
Source: ClinicalTrials.gov record NCT07447024. Inclusion in this directory is not an endorsement.